Title : Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.

Pub. Date : 2016 May

PMID : 27113739






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. Paclitaxel BRCA1 DNA repair associated Homo sapiens
2 The purpose of this study was to assess pathological complete response and whether it serves a surrogate for survival among patients receiving neo-adjuvant doxorubicin-cyclophosphamide followed by paclitaxel for triple-negative breast cancer with respect to BRCA1 mutation status. Paclitaxel BRCA1 DNA repair associated Homo sapiens